Carla Coffin

cscoffin@ucalgary.ca


In-person interactions impact on HCV, HIV, and Syphilis Rates in At Risk Populations

Pam Ford

Targeting the hepatitis B virus covalently closed circular DNA genome using a G-quadruplex specific single domain antibody

Simmone D'Souza

HDV is uncommon in Toronto but can have an aggressive clinical course: interim analysis

David Wong

Biologiste Médical

Ronald Simeon

Impact of COVID-19 pandemic–related measures on testing for hepatitis B in British Columbia, Canada: an interrupted time series analysis

Richard Morrow

Clinical Science Advances in Hepatitis B (HDV, HCV, HIV Co-infections): A Comprehensive Review

Moses Donkor

Epidemiology and Public Health Implications of Hepatitis B, HDV, HCV, and HIV Co-infections

Desmond Osei

EPIDEMIOLOGY, TREATMENT PATTERN, AND SURVIVAL IN CANADIAN PATIENTS WITH CHRONIC HEPATITIS B RELATED HEPATOCELLULAR CARCINOMA

Yashasavi Sachar

HCC RISK STRATIFICATION USING RANDOM SURVIVAL FORREST MACHINE LEARNING MODEL OUTPERFORMS TRADITIONAL ANALOG SCORING

Yashasavi Sachar

Hepatitis B core antibody is associated with liver fibrosis in people with HIV independently of MASLD

Dong Hyun (Danny) Kim

Initial HBV-Hepatocyte Genomic Integrations, Their Formation and Potential Role in Oncogenesis

Thomas Michalak

Investigating HDV screening rates and associated demographic characteristics among first-time HBV positive patients in Alberta from 2018-2022

Alexa Thompson

Compassionate use of REP 2139-Mg in HBV / HDV / HIV co-infection: a first Canadian experience

Sébastien Poulin

Functional cure of chronic HBV infection

David Wong

Using discrete field documentation in Epic EMR for clinical research of hepatitis B

David Wong

A DNA knot not like any other - exploring the specificity of HBV’s promoter G4-quadruplex

Archee Panwar

Intravital Imaging of the Liver Microenvironment in The Woodchuck Model of Hepatitis B Virus Infection

Layla Al-Yasiri

Chronic HBV infection in Toronto, Canada: Tale of two clinics

David Wong

Demographic Characteristics of Hepatitis B-Infected Sub-Saharan African Immigrants in Canada.

Nana Frimpong

Determining a Hepatitis Delta virus (HDV) peptidomimetic therapeutic to target Hepatitis B virus (HBV)

Justine Beghin

Anchoring Hepatitis B: Investigation of HBV promoter binding with zinc finger Specificity protein 1 and G4-quadruplex binding drugs

Samantha Polege

Epidemiology and Natural History of Chronic Hepatitis B in the Canadian Province of Alberta from 2012 to 2021: A Population-based Study

Golasa Samadi Kochaksaraei

Epidemiology, Linkage to Care and Natural History of Women of Childbearing Age with Chronic Hepatitis B: A Population-based Study

Golasa Samadi Kochaksaraei

Defining a Hepatitis D Virus Antibody Testing Algorithm for Accurate Screening

Carla Osiowy

IL-2 Produced by HBV-specific T cells as a Biomarker of Viral Control and Predictor of Response to PD-1 Therapy Across Clinical Phases of Chronic Hepa

Loghman Salimzadeh

Next Generation Sequence (NGS) Analysis for Hepatitis B Virus (HBV) Outbreak Transmission Analysis in Manitoba

Carla Osiowy

Prevalence and Clinical Characteristics of Hepatitis Delta Virus (HDV) Infected Individuals in British Columbia

Valeriya Zaborska

PSMA-Targeted Radionuclide Therapy of Hepatocellular Carcinoma in a Woodchuck Model

Hoda Poorbagher

G4Q-binding ligands: a starting point for potential cure therapies for chronic hepatitis B infections

Jessica Skoreyko

Cracking the HBV Code: Unravelling the specificity of SP1 with G-Quadruplex for next- generation cccDNA inhibitors

Kuldeep Kaur

Effect of HBV treatment on all-cause and liver-related death among individuals with HBV and cirrhosis in British Columbia: a population-based cohort

Jean Makuza

Hepatitis B Virus Genotype (GT) Does Not Influence Virological and Enzymatic Measures Over Time

Curtis Cooper

Prevalence of Hepatitis B Among Adults Receiving Immunosuppressive Therapy At a Tertiary Care Center in Saudi Arabia

Abdulrhman Alamr

Hepatocellular carcinoma (HCC) in patients followed in two clinics in Toronto

David Wong

Experience of a Chinese Hepatitis B Peer Support Group (PSG): Successes and Challenges

Colina Yim

Small molecules approach in HBV treatment:preventing transcription in the pre-core promoter by blocking a G-quadruplex with mithramycin and daunorubin

Kira Sviderskaia

Kinetics of Quantitative HBsAg Decline in Chronic Hepatitis B Patients Receiving Nucleos(t)ide Antiviral Therapy

Frank Hyun

Opening the X-files: Exploring HBx protein’s role in transcriptional enhancement

Emma Kasinyabo

Establishment of HBx responsive quantitative cell culture reporter system for monitoring HBV infection

Muhammad Atif Zahoor

Unravelling an important DNA knot – analysis of HBV’s promoter G4-quadruplex

Mohaddeseh Pakzamir

Production of recombinant woodchuck surface antigen and antibodies for use in ELISAs, ELISpots, and western blots

Michelle Tang

Anchoring Hepatitis B: Investigation of HBV promoter binding with zinc finger Specificity protein 1 and G4-quadruplex binding drugs

Samantha Polege

Guanine quadruplexes and host transcription factor interactions: Targeting viral cccDNA to treat chronic HBV.

Nikolas Shapka

Guanine quadruplexes and host transcription factor interactions: Targeting viral cccDNA to treat chronic HBV.

Nikolas Shapka

Jean Makuza

Under Review

Profile Summary

Submission ID PROS5BVGTDO
Name Jean Makuza
Call Progress toward Hepatitis B Elimination Meeting in Canada - Abstract Submission
Email Address jean.makuza@bccdc.ca
Title Student
Organization University of British Columbia

Session

Title Effect of HBV treatment on all-cause and liver-related death among individuals with HBV and cirrhosis in British Columbia: a population-based cohort
Description

Background
Hepatitis B virus (HBV) is a significant contributor to the liver disease burden.
Purpose
We assessed the effect of HBV treatment on all-cause and liver-related mortality among individuals with HBV and cirrhosis in British Columbia (BC), Canada.
Methods
Using data from the BC Hepatitis Testers Cohort, we included people with HBV and cirrhosis and followed them from their cirrhosis diagnosis date until death or December 31, 2020. We used multivariable Cox proportional hazard models and adjusted for time-varying treatment status and confounders.
Results:
Among 4,962 people with HBV and cirrhosis (2,386 treated), HBV treatment was associated with over 25% reduction of all-cause (aHR 0.75; 95% CI: 0.66, 0.85) and liver-related (asHR 0.74; 95% CI: 0.65, 0.83) mortality.
Conclusion:
HBV treatment reduced the risk of all-cause and liver-related mortality among individuals with cirrhosis. These findings highlight the need for early HBV diagnosis and treatment among people with cirrhosis.

Track Hepatitis B (including HDV, HCV, HIV Co-infections) - Epidemiology/Public Health
Formats
Audiences

Co-Presenters

Name Amanda Yu
Organization BC CDC
State/Province
City
Email amanda.yu@bccdc.ca
Website http://www.bccdc.ca/
Speaker Role
Name Dahn Jeong
Organization University of British Columbia
State/Province
City
Email dahn.jeong@bccdc.ca
Website http://www.bccdc.ca/
Speaker Role
Name Georgine Cua
Organization BC CDC
State/Province
City
Email georgine.cua@bccdc.ca
Website N/A
Speaker Role
Name Héctor A. Velásquez García
Organization BC CDC
State/Province
City
Email hector.velasquez@bccdc.ca
Website N/A
Speaker Role
Name Maria Alvarez
Organization BC CDC
State/Province
City
Email maria.alvarez@bccdc.ca
Website N/A
Speaker Role
Name Mawuena Binka
Organization BC CDC
State/Province
City
Email mawuena.binka@bccdc.ca
Website N/A
Speaker Role
Name Naveed Zafar Janjua
Organization British Columbia Centre for Disease Control/University of British Columbia
State/Province
City
Email naveed.janjua@bccdc.ca
Website N/A
Speaker Role
Name Prince Assumadu Adu
Organization BC CDC
State/Province
City
Email prince.adu@bccdc.ca
Website N/A
Speaker Role
Name Richard Morrow
Organization BC CDC
State/Province
City
Email richard.morrow@bccdc.ca
Website N/A
Speaker Role
Name Stanley Wong
Organization BC CDC
State/Province
City
Email stanley.wong@bccdc.ca
Website N/A
Speaker Role

Files

Submit Review



Is this abstract accepted for a poster presentation? *
Is this abstract accepted for a trainee travel grant?